Literature DB >> 21232801

Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial.

Mark C Gillies1, Ian L McAllister, Meidong Zhu, Wanling Wong, Damien Louis, Jennifer J Arnold, Tien Y Wong.   

Abstract

PURPOSE: To report the 24 months outcomes from a clinical trial of intravitreal triamcinolone acetonide (IVTA) plus laser versus laser treatment only in eyes with diabetic macular edema (DME).
DESIGN: Prospective, double-masked, randomized, placebo-controlled study. PARTICIPANTS: Eighty-four eyes of 54 participants were entered into the study, with 42 eyes randomly assigned to receive IVTA plus laser and 42 randomly assigned to receive laser treatment alone. Primary end point data were available for 71 (84.5%) eyes at 24 months, with last visual acuity observation carried forward for the remaining eyes.
METHODS: Best-corrected logarithm of minimum angle of resolution (logMAR) visual acuity and central macular thickness (CMT) by optical coherence tomography were measured after laser treatment preceded by either IVTA or sham. MAIN OUTCOMES MEASURES: The primary outcome was the proportion of eyes with improvement in visual acuity of 10 letters or more at 24 months. The secondary outcomes were mean visual acuity, requirement for further treatment, change in CMT, and adverse events.
RESULTS: At 24 months, improvement of 10 logMAR letters or more was seen in 15 (36%) of 42 eyes treated with IVTA plus laser compared with 7 (17%) of 42 eyes treated with laser only (P = 0.047; odds ratio, 2.79; 95% confidence interval, 1.01-7.67). There was no difference in the mean CMT or mean logMAR visual acuity between 2 groups. At least 1 retreatment was required in the second year of the study in 29 (69%) of 42 IVTA plus laser-treated eyes compared with 19 (45%) of 42 laser only eyes (P = 0.187). Cataracts were removed from 17 (61%) of 28 phakic IVTA plus laser-treated eyes versus 0 (0%) of 27 laser only eyes (P<0.001). Treatment for elevated intraocular pressure was required in 27 (64%) of 42 IVTA plus laser eyes compared with 10 (24%) of 42 laser only eyes (P<0.001).
CONCLUSIONS: Treatment with IVTA plus laser resulted in a doubling of improvement in vision by 10 letters or more compared with laser only over 2 years in eyes with DME, but is associated with cataract and raised intraocular pressure.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232801     DOI: 10.1016/j.ophtha.2010.09.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

Review 1.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Authors:  Bobak Bahrami; Meidong Zhu; Thomas Hong; Andrew Chang
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

Review 2.  Bioactive lipids and pathological retinal angiogenesis.

Authors:  Khaled Elmasry; Ahmed S Ibrahim; Samer Abdulmoneim; Mohamed Al-Shabrawey
Journal:  Br J Pharmacol       Date:  2018-11-19       Impact factor: 8.739

3.  Current treatments in diabetic macular oedema: systematic review and meta-analysis.

Authors:  John Alexander Ford; Noemi Lois; Pamela Royle; Christine Clar; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2013-03-01       Impact factor: 2.692

4.  Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet-Induced Diabetic Retinopathy.

Authors:  Rithwick Rajagopal; Gregory W Bligard; Sheng Zhang; Li Yin; Peter Lukasiewicz; Clay F Semenkovich
Journal:  Diabetes       Date:  2016-01-06       Impact factor: 9.461

5.  Macular laser photocoagulation with or without intravitreal triamcinolone pretreatment for diabetic macular edema: a result from five randomized controlled trials.

Authors:  Xiang-Dong Liu; Xiao-Dong Zhou; Zhi Wang; Yong-Ming Shen
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

6.  Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.

Authors:  Stephen G Schwartz; Harry W Flynn; Ingrid U Scott
Journal:  Curr Ophthalmol Rep       Date:  2013-09

Review 7.  Clinical trials on corticosteroids for diabetic macular edema.

Authors:  Hassan A Al Dhibi; J Fernando Arevalo
Journal:  World J Diabetes       Date:  2013-12-15

8.  Diabetic macular edema: therapeutic options.

Authors:  Amol D Kulkarni; Michael S Ip
Journal:  Diabetes Ther       Date:  2012-03-06       Impact factor: 2.945

9.  A three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema.

Authors:  Hee Yoon Cho; Se Woong Kang; Yun Taek Kim; Song Ee Chung; Seung Woo Lee
Journal:  Korean J Ophthalmol       Date:  2012-09-24

10.  Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema.

Authors:  Ying-Ying Yu; Yong Cheng; Li-Bin Chang; Hui-Ka Xia; Xiao-Xin Li
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.